50
Participants
Start Date
September 30, 2011
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
200 mg INX-08189 Fasted
200 mg capsule INX-08189 fasted x7 days
Placebo QD Fasted
Placebo capsule QD fasted x7 days
100 mg INX-08189 QD
100 mg INX-08189 capsule QD x 7 days
Placebo QD
Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
100 mg INX-08189 with low-fat meal
INX-08189 100 mg capsule, with low-fat meal QD for seven days
Placebo with low-fat meal
Placebo capsule administered with a low-fat meal QD for seven days
100 mg INX-08189 BID Fasted
100 mg INX-08189 BID fasted x7 days
Placebo BID Fasted
Placebo BID fasted x7 days
ribavirin
San Antonio
San Juan
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY